Sarcoma de Kaposi compromiso laringo-traqueal Caso broncoscópico y revisión de la literatura

Andrés Jiménez Quijano; Pedro Chaparro Mutis

Sarcoma de Kaposi compromiso laringo-traqueal Caso broncoscópico y revisión de la literatura

Kaposi Sarcoma: Laryngeal and tracheal involvement Endoscopic case and literature review

Publicado 2008-03-01

Abrir | Descargar

PDF FLIP

Número

Vol. 20 Núm. 1 (2008)

Sección

Reporte de caso

Cómo citar

Sarcoma de Kaposi compromiso laringo-traqueal Caso broncoscópico y revisión de la literatura .

rev. colomb. neumol. [Internet]. 2008 Mar. 1 [cited 2024 Dec. 26];20(1):26-30.

DOI

Licencia

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Andrés Jiménez Quijano

Fellow Cirugía de Tórax Hospital Santa Clara

Pedro Chaparro Mutis

Neumólogo, Jefe del servicio de broncoscopia Hospital Santa Clara.

Mostrar biografía de los autores

Paciente de sexo masculino de 19 años que consulta por primera vez hace 6 meses, de 60 días de evolución de dolor y masa a nivel anal, valorado de forma extrainstitucional por cirugía general y con diagnóstico de hemorroides externas es llevado a cirugía realizando una hemorroidectomía externa, con el reporte de patología se hace diagnóstico de Sarcoma de Kaposi.

Posteriormente con este diagnóstico es remitido a infectología donde solicitan una prueba de Elisa y Westernblot confirmatoria que reportan positivas para infección por virus de inmunodeficiencia (HIV) además un recuento de linfocitos CD4 de 47 y carga viral de 400.000 copias.

Visitas del artículo 29 | Visitas PDF 61

Descargas

Los datos de descarga todavía no están disponibles.

Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi’s sarcoma: epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 1993;28:371–395.
Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic Kaposi sarcoma: epidemiology and risk factors. Cancer 2000;88:500–517.
Friedman-Kien AE, Saltzman BR. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi’s sarcoma. J Am Acad Dermatol 1990;22:1237–1250.
Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002;2:281–292.
Penn I. Sarcomas in organ allograft recipients. Transplantation 1995;60:1485–1491.
Stafford ND, Herdman RC, Forster S, Munro AJ. Kaposi’s sarco- ma of the head and neck in patients with AIDS. J Laryngol Otol 1989;103:379–82.
Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990;335: 123–128.
Wahman A, Melnick SL, Rhame FS, Potter JD. The epidemiology of classic, African, and immunosuppressed Kaposi’s sarcoma. Epidemiol Rev 1991;13:178–199.
Haramati LB, Wong J. Intrathoracic Kaposi’s sarcoma in women with AIDS. Chest 2000;117:410–414.
Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770–776.
Gill PS, Akil B, Colletti P, et al. Pulmonary Kaposi’s sarcoma: clinical findings and results of therapy. Am J Med 1989;87:57–61.
Chachoua A, Krigel R, Lafleur F, et al. Prognostic factors and staging classification of patients with epidemic Kaposi’s sarcoma. J Clin Oncol 1989;7:774–780.
Niedt GW, Schinella RA. Acquired immunodeficiency syndrome: clinicopathologic study of 56 autopsies. Arch Pathol Lab Med 1985;109:727–734.
Abemayor E, Calcaterra TC. Kaposi’s sarcoma and communityacquired immune deficiency syndrome. Arch Otolaryngol 1983;109:536–542.
Stafford ND, Herdman RC, Forster S, Munro AJ. Kaposi’s sarcoma of the head and neck in patients with AIDS. J Laryngol Otol 1989;103:379–382.
Greenberg JE, Fischl MA, Berger JR. Upper airway obstruction secondary to acquired immunodeficiency syndrome-related Kaposi’s sarcoma. Chest 1985;88:638–40.
Roy TM, Dow FT, Puthuff DL. Upper airway obstruction from AIDS-related Kaposi’s sarcoma. J Emerg Med 1991;9:23–5.
Carlos S. Restrepo,Santiago Martínez,Julio A. Lemos,Jorge A. Carrillo, MD. Imaging Manifestations of Kaposi Sarcoma. RadioGraphics 2006; 26:1169–1185.
Mochloulis G, Irving RM, Grant HR, Miller RF. Laryngeal Kaposi’s sarcoma in patients with AIDS. J Laryngol Otol 1996;110:1034–7.
Gallant JE, Moore RD, Richman DD, et al. Risk factors for Kaposi’s sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. Arch Intern Med 1994; 154: 566-572.
International Collaboration on HIV and Cancer Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-1830.
Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses ocurring after initiation of potent antiretroviral therapy: the Swiss Cohort Study. JAMA 1999; 282: 2220-2226.
Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS 1998; 12: 45-49.
Bower M, Fox P, Fife K, et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. AIDS 1999; 13: 2105-2111.
Cattelan AM, Calabro ML, Aversa SM, etal. Regression of AIDS related Kaposi’s sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 1999; 35: 1809-1815.
Dupin N, Rubin de Cervens V, Gorin I, et al. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi’s sarcoma. Br J Dermatol 1999; 140: 875-881.
Bourboulia D, Aldam D, Lagos D, et al. Short and long term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpes virus immune responses and viraemia. AIDS 2004; 20: 485-493.
Real FX, Oettgen HF, Krown SE: Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 4 (4): 544-51, 1986.
Groopman JE, Gottlieb MS, Goodman J, et al.: Recombinant alpha 2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 100 (5): 671-6, 1984.
Tulpule A, Joshi B, DeGuzman N, et al. Interleukin-4 in the treatment of AIDS-related Kaposi’s sarcoma. Ann Oncol 1997; 8: 79-83.
Lane HC, Kovacs JA, Feinberg J, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposis’s sarcoma. Lancet 1988; 2: 1218-1222.
Gill PS, Rarick MU, McCutchan JA, et al. Systemic treatment of AIDS-related Kaposi’s sarcoma: results of a randomized trial. Am J Med 1991; 90: 427-433.
Nuñez M, Saballs PValencia ME, et al. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi’s sarcoma receiving highly active antiretroviral therapy. HIV Clin Trials 2001; 2: 429-437.
Stebbing J, Wildfire A, Portsmouth S, et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi’s sarcoma: clinical and angiogenic correlations. Ann Oncol 2003; 14: 1660-1666.
Lozada F, Silverman S, Migliotari CA, et al. Oral manifestations of tumor and opportunistic infections in the acquired immunodeficiency syndrome (AIDS): findings in 53 homosexual men with Kaposi’s sarcoma. Oral Surg 1983; 56: 491-494.
Chak, L.; Gill, P.S.; Levine, A.M.; Meyer, A.M.; Anselmo, J.A.; Petrovitch, Z. Radiation therapy for acquired immunodeficiency syndrome-related Kaposi’s sarcoma. J. Clin. Oncol 1988; 6:863-867.